Investing
Pfizer, BioNtech say flu-COVID shot generates immune response
© Reuters. A compagny logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo
(Reuters) – Pfizer (NYSE:) and German partner BioNTech (NASDAQ:) said on Thursday that their vaccine to prevent flu and COVID-19 generated a strong immune response against the virus strains in early- to mid-stage trials.
The companies said they plan to start a late-stage trial in the coming months.
Read the full article here
-
Side Hustles6 days ago
How to Be Unapologetically You and Why It Matters
-
Side Hustles6 days ago
With AI Magicx, It’s Like Getting an Entire Creative Team in One Money-Saving AI Tool
-
Investing5 days ago
Nvidia CEO Jensen Huang: Demand For Blackwell AI Is Insane
-
Side Hustles5 days ago
Mark Zuckerberg Is Now Second Richest Person in the World
-
Passive Income6 days ago
How AI-Driven Personalization Is Transforming the Retail Industry
-
Investing3 days ago
Hurricane Helene Hits Spruce Pine Mine, Quartz Used for Tech
-
Investing5 days ago
BCA says investors should fade the real estate rally By Investing.com
-
Side Hustles5 days ago
Meta Previews Movie Gen, AI Tools That Turn Dreams to Videos